CETP Inhibitor Pipeline: Obicetrapib — PatSnap Eureka
CETP Inhibitor Pipeline: Obicetrapib & Next-Generation HDL Modulation
From the failures of torcetrapib to the precision medicine era of obicetrapib and ADCY9 pharmacogenomics — explore the full CETP inhibitor landscape with AI-powered patent and literature intelligence from PatSnap Eureka.
CETP: A Contested but Validated Cardiovascular Target
Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that mediates the heteroexchange of cholesteryl esters (CE) from HDL to apoB-containing lipoproteins (VLDL, LDL) against triglycerides (TG), thereby depleting HDL-CE and enriching pro-atherogenic LDL and VLDL fractions. This central role in reverse cholesterol transport (RCT) and lipoprotein remodeling has made CETP a target of sustained pharmaceutical interest over nearly two decades.
Three mechanistic rationales have evolved over time: (1) the original HDL-C raising hypothesis, grounded in epidemiologic evidence of an inverse relationship between HDL-C and coronary heart disease (CHD) risk; (2) a reframed apoB/LDL-C lowering paradigm, supported by Mendelian randomization (MR) and the REVEAL trial; and (3) emerging recognition that not all HDL particles raised by CETP inhibition are functionally equivalent or protective.
A critical biological complexity is HDL heterogeneity. Research from Monash University and Victorian Heart Institute documents that pharmacological CETP inhibition increased HDL subspecies containing apoC3 — a fraction epidemiologically associated with higher CHD risk — potentially explaining why aggregate HDL-C elevation failed to reduce cardiovascular events in earlier trials. Published clinical evidence from McGill University further articulates the shift: CETP inhibitors are now understood to reduce major adverse cardiovascular events (MACE) primarily through lowering of non-HDL-C and apoB, not through HDL-C elevation per se.
Drug-target Mendelian randomization of CETP protein concentration, conducted by UCL British Heart Foundation Research Accelerator, confirms that on-target CETP inhibition is expected to reduce risk of CHD, heart failure, and diabetes, while increasing the risk of age-related macular degeneration. This validates continued investment in next-generation agents with differentiated selectivity profiles.
Five CETP Inhibitors: Mechanisms, Trials & Current Status
From first-in-class torcetrapib to next-generation obicetrapib — a comparative view of compound-level evidence from patent filings and academic literature.
| Compound | Key Mechanism | Key Trial / Evidence | Status | Lead Assignee |
|---|---|---|---|---|
| Torcetrapib | Full CETP inhibition; off-target aldosterone/cortisol activation | Phase 3 — excess mortality; off-target toxicity identified by UCSD network pharmacology | Discontinued | Pfizer |
| Dalcetrapib | Requires Cys-13 on CETP; conformational modulation; preserves pre-β-HDL; partial CE transfer reduction | dal-OUTCOMES (negative); dal-GenE: 6,147 ADCY9 AA patients, HR ~0.90 over 39.9 months | Phase 3 / PGx | DalCor Pharmaceuticals |
| Anacetrapib | Binds concave N-terminal tunnel of CETP; increases VLDL-TG FCR +29%; improves cholesterol efflux capacity (CEC) | REVEAL trial — only CETP inhibitor to reduce CHD events in large outcomes trial; DEFINE substudy confirmed CEC improvement | Phase 3 (REVEAL ✓) | Merck & Co. |
| Evacetrapib | Potent CETP inhibition; concentration-dependent HDL-C and LDL-C effects on statin background (Cleveland Clinic PK/PD) | ACCELERATE trial — negative Phase 3 outcomes; ACCENTUATE substudy: apoC3-HDL subspecies increase documented | Discontinued | Eli Lilly |
Search the full CETP inhibitor patent landscape
Access 100M+ patent records and 200M+ literature sources with AI-powered analysis in PatSnap Eureka.
Mechanistic Evidence Across CETP Inhibitor Modalities
Key quantitative signals from patent and literature analysis — clinical trial endpoints, pharmacogenomic data, and novel scaffold potency.
dal-GenE Trial: Primary Endpoint Event Rates
In 6,147 ADCY9 rs1967309 AA genotype patients with ACS, dalcetrapib reduced primary endpoint events from 10.6% (placebo) to 9.5% (treatment) over 39.9 months — directional but non-significant (HR ~0.90).
CETP Inhibitor Therapeutic Modalities
Four distinct therapeutic modalities identified across retrieved patent and literature records: small-molecule inhibitors dominate (5 compounds), with ASO, pharmacogenomics-guided, and structural biology approaches emerging.
Anacetrapib: VLDL-TG Fractional Catabolic Rate Effect
Columbia University kinetic studies demonstrate anacetrapib increases VLDL-TG fractional catabolic rate (FCR) by +29%, independently of changes in apoC-II or apoC-III production rates — a key mechanism for TG lowering.
Key Assignee & IP Activity Landscape
Patent activity is concentrated in a small number of commercial assignees. F. Hoffmann-La Roche AG holds multiple active pharmacogenomics patents (IL, JP, RS); NewAmsterdam Pharma holds the active obicetrapib combination patent (BR, 2023).
Beyond Small Molecules: ASO, Pharmacogenomics & Structural Design
Retrieved patent and literature evidence identifies four distinct approaches to CETP inhibition, each with differentiated mechanisms and development stages.
Small-Molecule CETP Inhibitors
The dominant modality across retrieved results, with five compounds studied. Anacetrapib binds the concave N-terminal tunnel surface of CETP (Tampere University molecular dynamics). Dalcetrapib requires cysteine-13 on CETP and induces conformational change, modulating rather than fully inhibiting CE transfer and preserving pre-β-HDL formation. PatSnap life sciences intelligence tracks all active small-molecule IP in this class.
Anacetrapib: only compound to reduce CHD in outcomes trial (REVEAL)Antisense Oligonucleotide (ASO) CETP Inhibition
Ionis Pharmaceuticals' ASO CETP inhibitor produced comparable reductions in total plasma cholesterol and CETP activity versus anacetrapib in hyperlipidemic CETP-transgenic LDLr-knockout mice, but — critically — enhanced macrophage reverse cholesterol transport (RCT), which anacetrapib did not replicate. ASO-mediated knockdown was also associated with reduced hepatic lipid accumulation. No human clinical data appear in retrieved results. NIH-funded oligonucleotide delivery research has advanced substantially since the 2013 preclinical publication.
Superior macrophage RCT enhancement vs. small molecules (preclinical)Pharmacogenomics-Guided Therapy (ADCY9)
Multiple F. Hoffmann-La Roche AG patent filings (JP, RS, IL jurisdictions) claim genotyping methods for identifying cardiovascular patients likely to benefit from CETP inhibitors, centered on SNPs in the ADCY9 locus: rs1967309, rs11647778, rs12595857, and others. The dal-GenE trial (DalCor Pharmaceuticals, 2022) enrolled 6,147 patients with the ADCY9 rs1967309 AA genotype and demonstrated directional cardiovascular benefit (HR ~0.90) over 39.9 months. PatSnap analytics can map Roche's multi-jurisdictional ADCY9 patent estate.
dal-GenE: 9.5% vs 10.6% primary endpoint event rateStructural Biology & Novel Scaffold Design
Shenyang Pharmaceutical University researchers designed N,N-disubstituted-4-arylthiazole-2-methylamine derivatives as CETP inhibitors, with compound 30 achieving IC50 = 0.79 μM. Structure-activity relationship (SAR) data indicate that electron-donor groups on ring A and electron-withdrawing groups at the 4-position of ring B are critical for potency. F. Hoffmann-La Roche also characterized RG7232, a short-half-life CETP inhibitor (t½ ~3 hours) with "on/off" kinetics modeled using PK/PD frameworks for pre-β-HDL levels and RCT rates. EPO patent databases contain the full scaffold IP landscape.
IC50 = 0.79 μM for lead thiazole derivative (compound 30)Strategic Implications for IP & R&D Teams
Key signals from patent filings and clinical evidence — what the CETP inhibitor landscape means for drug discovery, IP strategy, and trial design.
Target Validation Is Robust — Compound Selection Is Critical
Mendelian randomization data from UCL confirm that on-target CETP inhibition reduces CHD, heart failure, and diabetes risk. The class's clinical history represents compound failures (torcetrapib off-target toxicity; dalcetrapib/evacetrapib insufficient potency), not target failure. This validates continued investment in next-generation agents like obicetrapib with differentiated selectivity profiles.
Obicetrapib + Ezetimibe: Commercially Differentiated IP Position
The NewAmsterdam Pharma combination patent targets a clinically underserved population (~10–20% of statin-prescribed patients) where LDL-C management options are limited, reducing competitive crowding from statin + PCSK9 inhibitor combinations. The obicetrapib + ezetimibe combination provides additive LDL-C lowering without statin use.
Obicetrapib + Ezetimibe and Emerging Regimens
The most clinically and commercially advanced combination signal in this dataset is obicetrapib + ezetimibe. The NewAmsterdam Pharma B.V. patent (BR, 2023) explicitly claims this combination for statin-intolerant patients with hyperlipidemia or mixed dyslipidemia. The combination rationale is mechanistically coherent: obicetrapib lowers LDL-C and non-HDL-C via CETP inhibition while ezetimibe reduces intestinal cholesterol absorption — additive LDL-C lowering without statin use. Retrieved results suggest this targets an unmet need in statin-intolerant populations.
Across retrieved results, anacetrapib, evacetrapib, and dalcetrapib were all studied on atorvastatin or rosuvastatin backgrounds. The metabolic synergy is documented: atorvastatin + anacetrapib produced greater VLDL apoE FCR increases than anacetrapib alone, and statin co-administration altered apoC-III kinetics in CETP inhibitor studies (Columbia University). Retrieved results consistently position CETP inhibitors as add-on to statin therapy in non-statin-intolerant populations.
F. Hoffmann-La Roche AG patent filings active in multiple jurisdictions (IL, JP, RS) through 2023 and the DalCor dal-GenE clinical trial together constitute a coordinated precision medicine program. Signals suggest that genotype-selected CETP inhibitor therapy — rather than population-wide dosing — may be the viable path forward for dalcetrapib specifically.
Retrieved results from multiple groups (Duke University, UT Southwestern, Victorian Heart Institute, Monash University) converge on the signal that aggregate HDL-C is an insufficient endpoint, and that cholesterol efflux capacity (CEC), HDL subspecies composition, and anti-inflammatory capacity are more predictive functional measures. Future CETP inhibitor trials may incorporate CEC or HDL particle composition as primary or co-primary endpoints.
CETP Inhibitor Pipeline — key questions answered
Torcetrapib was withdrawn from Phase 3 development due to excess mortality driven by off-target aldosterone/cortisol pathway activation causing hypertension, unrelated to CETP inhibition per se. Computational network pharmacology analysis from the University of California San Diego identified a panel of off-target protein interactions responsible for these adverse effects, distinguishing compound toxicity from target failure.
McGill University research reframes the mechanistic basis for CETP inhibitor efficacy: cardiovascular event reduction is principally mediated by lowering of apoB-containing atherogenic particles, not by HDL-C elevation per se. This reconceptualization aligns CETP inhibitors closer to LDL-lowering agents such as statins and PCSK9 inhibitors than to HDL therapies.
NewAmsterdam Pharma B.V. holds a patent (BR jurisdiction, 2023) explicitly claiming the combination of obicetrapib and ezetimibe for statin-intolerant patients with hyperlipidemia or mixed dyslipidemia. The combination rationale is mechanistically coherent: obicetrapib lowers LDL-C and non-HDL-C via CETP inhibition while ezetimibe reduces intestinal cholesterol absorption—additive LDL-C lowering without statin use.
Multiple F. Hoffmann-La Roche AG patent filings claim genotyping methods and companion diagnostic compositions for identifying cardiovascular disease patients likely to benefit from CETP inhibitors, centered on SNPs in the ADCY9 locus (rs1967309, rs11647778, rs12595857, and others). The dal-GenE trial enrolled 6,147 patients with the ADCY9 rs1967309 AA genotype and demonstrated directional but non-statistically significant cardiovascular benefit (HR for primary endpoint ~0.90) over median 39.9 months follow-up.
Ionis Pharmaceuticals preclinical work in hyperlipidemic CETP-transgenic LDLr-knockout mice showed that an ASO CETP inhibitor produced comparable reductions in total plasma cholesterol and CETP activity versus anacetrapib, but—critically—enhanced macrophage reverse cholesterol transport (RCT), which anacetrapib did not replicate. The authors attribute this to differences in HDL apolipoprotein composition and reductions in plasma TG observed only with the ASO. Additionally, ASO-mediated CETP mRNA knockdown was associated with reduced hepatic lipid accumulation compared to the small-molecule inhibitor.
The Victorian Heart Institute/Monash University paper demonstrates that CETP inhibitors (specifically evacetrapib) increase HDL subspecies containing apoC3, a variant associated with increased CHD risk. This HDL compositional shift may explain residual cardiovascular risk despite aggregate HDL-C elevation and is a critical mechanistic caveat for next-generation compound development.
Still have questions? Let PatSnap Eureka answer them with live patent and literature intelligence.
Ask Eureka About CETP InhibitorsAccelerate Your CETP Inhibitor Research with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search obicetrapib patents, ADCY9 pharmacogenomics filings, and the full CETP inhibitor landscape in one platform.
References
- Pharmacological Inhibition of CETP Increases HDL That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease — Victorian Heart Institute, Monash University, 2022
- Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels — McGill University Health Centre, 2022
- Antisense Oligonucleotide Inhibition of Cholesteryl Ester Transfer Protein Enhances RCT in Hyperlipidemic, CETP Transgenic, LDLr-/- Mice — Ionis Pharmaceuticals, 2013
- Pharmacogenetics-Guided Dalcetrapib Therapy After an Acute Coronary Syndrome: the dal-GenE Trial — DalCor Pharmaceuticals, 2022
- Effects of CETP Inhibition with Anacetrapib on Metabolism of VLDL-TG and Plasma Apolipoproteins C-II, C-III, and E — Columbia University, 2017
- Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on VLDL Apolipoprotein E Metabolism — USDA Human Nutrition Research Center, Tufts University, 2008
- How Anacetrapib Inhibits the Activity of the Cholesteryl Ester Transfer Protein? Perspective through Atomistic Simulations — Tampere University of Technology, 2014
- Design, Synthesis, and Biological Evaluation of N,N-Disubstituted-4-Arylthiazole-2-Methylamine Derivatives as Cholesteryl Ester Transfer Inhibitors — Shenyang Pharmaceutical University, 2017
- Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin-Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidemia — NewAmsterdam Pharma B.V., 2023 (BR)
- Genetic Markers for Predicting Responsiveness to Treatment with HDL-Raising Agents or HDL Mimetic Agents — F. Hoffmann-La Roche AG, 2017 (JP)
- Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent — F. Hoffmann-La Roche AG, 2022 (IL)
- Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors — University of California San Diego, 2009
- Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib — DalCor Pharmaceuticals UK Limited, 2018
- Analysis of "On/Off" Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics — F. Hoffmann-La Roche, 2015
- PubMed / National Library of Medicine — CETP inhibitor clinical trial literature
- National Institutes of Health (NIH) — oligonucleotide therapeutics and cardiovascular research
- National Human Genome Research Institute — pharmacogenomics and precision medicine
- European Patent Office (EPO) — CETP inhibitor patent landscape
- UCL British Heart Foundation Research Accelerator — Mendelian randomization of CETP as drug target
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.